New! Sign up for our free email newsletter.
Science News
from research organizations

Opening a new door to immunity

Researcher uncovers clue to as to how disease processes develop

Date:
May 11, 2018
Source:
University of Missouri-Columbia
Summary:
A new study could have major implications for our understanding of disease processes for conditions such as autoimmunity, atherosclerosis and heart failure, potentially leading to better prevention and treatment.
Share:
FULL STORY

A new study could have major implications for our understanding of disease processes for conditions such as autoimmunity, atherosclerosis and heart failure, potentially leading to better prevention and treatment.

Dr. Edward T.H. Yeh, chairman of the Department of Medicine and director of the Center for Precision Medicine at the University of Missouri School of Medicine, has been leading a team of researchers at MU and in Shanghai, China, in examining innate immunity, a critical arm of the immune system responsible for fending off external threats from infections.

"What we were trying to figure out is how the immune response is regulated," Yeh said.

The innate immune response can be activated by a family of proteins called Toll-like receptors (TLRs). TLR signaling is responsible for maintaining immune homeostasis, which is the process of keeping the immune system stable. TLR signaling must be balanced just so -- both hyperactivation and hypoactivation cause disease in humans.

What Yeh and his team found is that a key signaling protein known as TRAF6 is kept in check by an inhibitory protein called sNASP to prevent accidental firing of the innate immune response. Animal studies supported this discovery -- mice with a mutation that caused sNASP proteins to bind to TRAF6 proteins all the time were more susceptible to septic infection.

"The innate immune response is a critical component of immunity. Our finding identifies a novel way that immune response can be controlled, which can be translated to many human diseases, such as atherosclerosis, autoimmunity and heart failure," Yeh said.

Experiments are in progress to study how sNASP mutations would affect the development of atherosclerosis and heart failure.

Dr. Yeh holds the endowed Frances T. McAndrew Chair at the University of Missouri and his laboratory is supported by grants from the National Institute of Health and by MU's strategic hire program.

The study appears in the Journal of Clinical Investigation, published by the American Society for Clinical Investigation.


Story Source:

Materials provided by University of Missouri-Columbia. Note: Content may be edited for style and length.


Journal Reference:

  1. Feng-Ming Yang, Yong Zuo, Wei Zhou, Chuan Xia, Bumsuk Hahm, Mark Sullivan, Jinke Cheng, Hui-Ming Chang, Edward T.H. Yeh. sNASP inhibits TLR signaling to regulate immune response in sepsis. Journal of Clinical Investigation, 2018; DOI: 10.1172/JCI95720

Cite This Page:

University of Missouri-Columbia. "Opening a new door to immunity." ScienceDaily. ScienceDaily, 11 May 2018. <www.sciencedaily.com/releases/2018/05/180511123221.htm>.
University of Missouri-Columbia. (2018, May 11). Opening a new door to immunity. ScienceDaily. Retrieved June 23, 2024 from www.sciencedaily.com/releases/2018/05/180511123221.htm
University of Missouri-Columbia. "Opening a new door to immunity." ScienceDaily. www.sciencedaily.com/releases/2018/05/180511123221.htm (accessed June 23, 2024).

Explore More

from ScienceDaily

RELATED STORIES